Announcements Trials
Browse Landscape

Status

Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 4Neoplasms 3Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Adenocarcinoma of Lung 2Stomach Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 9pembrolizumab 7Pemetrexed 7Radiotherapy 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiation 4Nivolumab 4Bevacizumab 4Platinum 3Paclitaxel 3Mastectomy, Segmental 3Cisplatin 3Biopsy 3fludarabine phosphate 2durvalumab 2capmatinib 2aldesleukin 2Taxes 2Radiotherapy, Conformal 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2Anterior Temporal Lobectomy 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × capmatinib × 1 year × Clear all
NCT05703516 2026-06-01

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Novartis

Recruiting
44 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡